The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb has opened a $160M radiopharma facility in Indianapolis, scaling up production since acquiring RayzeBio ...

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

Nuclidium’s radiopharmaceutical platform is unique in its use of copper-based payloads, which the biotech claims can deliver higher doses while also being safer.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.